- Email: [email protected]
Temporal relationship between impaired water excretion and hypersecretion of antidiuretic hormone (ADH) in rats with experimental cirrhosis
57
TEMPORAL RELATIONSHIP BETWEEN IMPAIRED WATER EXCRETION AND HYPERSECRETION OF ANTIDIURETIC HORMONE (ADH) IN RATS WITH EXPERIMENTAL CIRRHOSIS. J . Camps, J. Sol~, V. Arroyo, J. Gaya, A. Rimola, RM P~rez-Ayuso, F. Rivera and J. Rod,s. Liver Unit and Hormonal Laboratory. Hospital Clinic i Provincial. University of Barcelona. Spain.
An impairment of the renal ability to excrete free water is common in cirrhosis with ascites. However, at present it is not known whether this disorder is due to an increased proximal sodium reabsorption or to a non-osmotic hypersecretion of ADH. To investigate the temporal relationship between the onset of water retention and ADH hypersecretion in cirrhosis, free water excretion (estimated by the minimum urinary osmolality) and urinary ADH excretion (which correlates with plasma ADH) were weekly measured after an oral water load in 18 rats submitted to a cirrhosis induction program with CCI 4 (CT rats) and in 20 control animals. The onset of ascites in CT rats was estimated by sequential paracentesis. Thirteen CT rats (CT-I rats) developed an impairment of water excretion 1 to 5 weeks after the onset of ascites. Five CT rats (CT-2 rats) did not present this abnormality in spite of developing ascites. The urinary excretion of ADH in CT-I rats which was normal before the impairment of water excretion (22.0 + 2.9 pg/h), increased markedly within the week in which this abnormality was first detected (58.9 ~ 8.0 pg/h, p
58
EFFECTS OF HTLV III VIRUS INFECTION ON REPLICATION, SEVERITY OF LIVER DISEASE AND RESPONSE TO INTERFERON IN CHRONIC HEPATITIS B VIRUS CARRIERS. L....Caruso, *J.N. Weber, *~.E. Forster, L. Scully, *J.R.W. Harris H.C. Thomas. Department of Medicine, Royal Free Hospital, London, England, and *Praed Street Clinic, St Mary's Hospital, London, England.
18 patients entering a randomised controlled study of the effects of recoml3inant alpha 2 interferon (Roche) on HBV virus infection were screened for HTLV III antibody. 44% of the patients were anti-HTLV III positive in an indirect in~nunofluorescence assay using infected lymphoblastoid cells as a substrate. HBV-DNA concentrations in serum were similar in anti-HTLV III positive and negative patients: Mean ± SEM, 2326 ± iOO pg/ul vs =984 ± 169. Examination of the liver biopsies showed that in the anti-HTLV III positive group, only 2/8 showed chronic active hepatitis whereas 8/10 showed this lesion in the anti-HTLV III negative group. Aspartate aminotransferase sertm~ levels were lower in the positive patients: Mean ± SEM, 39 ± 7 IU/I vs 56 ±7 (p=O.O5). 4/10 patients without HTLV III infection had responded to recombinant alpha interferon treatment within 6 months of therapy. However, in the anti-HTLV III positive group, 0/8 patients had responded by this time. Conclusion: HTLV III infection is common in h(~nosexual patients with chronic HBV infection and appears to decrease the severity of the liver disease. Preliminary data suggest that these patients are less likely to respond to interferon treatment than those HBV carriers without this infection.
$207
TEMPORAL RELATIONSHIP BETWEEN IMPAIRED WATER EXCRETION AND HYPERSECRETION OF ANTIDIURETIC HORMONE (ADH) IN RATS WITH EXPERIMENTAL CIRRHOSIS. J . Camps, J. Sol~, V. Arroyo, J. Gaya, A. Rimola, RM P~rez-Ayuso, F. Rivera and J. Rod,s. Liver Unit and Hormonal Laboratory. Hospital Clinic i Provincial. University of Barcelona. Spain.
An impairment of the renal ability to excrete free water is common in cirrhosis with ascites. However, at present it is not known whether this disorder is due to an increased proximal sodium reabsorption or to a non-osmotic hypersecretion of ADH. To investigate the temporal relationship between the onset of water retention and ADH hypersecretion in cirrhosis, free water excretion (estimated by the minimum urinary osmolality) and urinary ADH excretion (which correlates with plasma ADH) were weekly measured after an oral water load in 18 rats submitted to a cirrhosis induction program with CCI 4 (CT rats) and in 20 control animals. The onset of ascites in CT rats was estimated by sequential paracentesis. Thirteen CT rats (CT-I rats) developed an impairment of water excretion 1 to 5 weeks after the onset of ascites. Five CT rats (CT-2 rats) did not present this abnormality in spite of developing ascites. The urinary excretion of ADH in CT-I rats which was normal before the impairment of water excretion (22.0 + 2.9 pg/h), increased markedly within the week in which this abnormality was first detected (58.9 ~ 8.0 pg/h, p
58
EFFECTS OF HTLV III VIRUS INFECTION ON REPLICATION, SEVERITY OF LIVER DISEASE AND RESPONSE TO INTERFERON IN CHRONIC HEPATITIS B VIRUS CARRIERS. L....Caruso, *J.N. Weber, *~.E. Forster, L. Scully, *J.R.W. Harris H.C. Thomas. Department of Medicine, Royal Free Hospital, London, England, and *Praed Street Clinic, St Mary's Hospital, London, England.
18 patients entering a randomised controlled study of the effects of recoml3inant alpha 2 interferon (Roche) on HBV virus infection were screened for HTLV III antibody. 44% of the patients were anti-HTLV III positive in an indirect in~nunofluorescence assay using infected lymphoblastoid cells as a substrate. HBV-DNA concentrations in serum were similar in anti-HTLV III positive and negative patients: Mean ± SEM, 2326 ± iOO pg/ul vs =984 ± 169. Examination of the liver biopsies showed that in the anti-HTLV III positive group, only 2/8 showed chronic active hepatitis whereas 8/10 showed this lesion in the anti-HTLV III negative group. Aspartate aminotransferase sertm~ levels were lower in the positive patients: Mean ± SEM, 39 ± 7 IU/I vs 56 ±7 (p=O.O5). 4/10 patients without HTLV III infection had responded to recombinant alpha interferon treatment within 6 months of therapy. However, in the anti-HTLV III positive group, 0/8 patients had responded by this time. Conclusion: HTLV III infection is common in h(~nosexual patients with chronic HBV infection and appears to decrease the severity of the liver disease. Preliminary data suggest that these patients are less likely to respond to interferon treatment than those HBV carriers without this infection.
$207